If you're planning to be in Boston December 3-5 for Hanson Wade Group's 6th Annual Cell Therapy Analytical Development Summit and would like to touch base with DHC, reach out to Joshua Beckett, who will be in attendance. See you there! https://lnkd.in/dWKjYS3
Dark Horse Consulting Group Inc.
生物技术研究
Walnut Creek，California 7,563 位关注者
Cell and Gene Therapy Experts
关于我们
AT DARK HORSE CONSULTING, we work to accelerate cell and gene therapies through our unmatched expertise. Our consulting team has extensive CGT industry experience with knowledge spanning manufacturing, process development, comparability, analytical dev, quant modeling, quality systems, regulatory support, preclinical dev, device dev, program management, facility design and engineering, market research, and due diligence and business strategy. Many of our consultants also bring experience from adjacent, more mature, sectors, including traditional biologics, small molecules, medical devices, and management consulting. Client requests range from scientific expertise to tactical needs to strategic considerations to business development. We understand the unique challenges faced by Cell and Gene Therapy developers like none other. We apply best practices from across this and other industries to address the needs of our clients, who range from biopharmaceutical companies to tools & tech providers to investment firms.
- 网站
-
https://www.darkhorseconsultinggroup.com
Dark Horse Consulting Group Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Walnut Creek，California
- 类型
- 私人持股
- 创立
- 2014
- 领域
- manufacturing support、process development and comparability、regulatory support、quality systems、analytical development、quantitative modeling、device development、preclinical development、project & program management、market research、intellectual property、financing and due diligence、cell therapy、gene-modified cell therapy、gene therapy和cell and gene therapy
地点
Dark Horse Consulting Group Inc.员工
动态
-
Save the date and watch this space/your email for forthcoming RSVP details for the 2nd Annual DHC CGT Investment Landscape Forum, taking place on January 15, 2025 in San Francisco at #JPM25. The first panel, "Lessons learned from recent commercial launches: how recent commercial launches inform strategies for tomorrow" will be chaired by Reni Benjamin, Managing Director/Biotech Equity Research at JMP Securities. The second panel, "Emerging answers to current challenges in CGT: how technical evolution will enable broader and more effective marketplace acceptance of CGT" will be chaired by Ron Glickman, Managing Director and Head of BD at Chardan Capital Markets. We look forward to seeing you there.
-
-
ICYMI, you can watch yesterday's Unbridled Excellence webinar ("Unique Considerations for Development of IND Strategy for Viral and Non-Viral Gene Editing," hosted by Elizabeth Figueroa and Christina Fuentes, Ph.D.) on-demand here: https://lnkd.in/gpZBgZz7
-
-
Our clinical team together at DHC's Rocky Mountain office: Head of Clinical Adnan Jaigirdar, MD, FACS and Master Practice Expert Kristin Baird, MD!
-
-
One week from today, join Alliance for Regenerative Medicine's webinar on "Commercialization Strategies for Cell and Gene Therapies" to hear from Rob Allen and Sarah Creviston, moderated by Delara Motlagh. Additional details below?; register here: https://lnkd.in/gEG8xKXe!
Upcoming webinar: Commercial Strategies for Cell and Gene Therapies ?? November 20, 2024 ?? 11:00am - 12:00pm ET Join ARM and Catalent Pharma Solutions as we present a captivating webinar series featuring distinguished executive leaders at the forefront of the cell and gene therapy sector. This live webinar will discuss the critical steps required to successfully bring cell and gene therapies to market. Register here: https://lnkd.in/gEG8xKXe Moderator: Delara Motlagh, Ph.D. Vice President, Global Cell Therapy and Plasmid DNA, Catalent Pharma Solutions Featured Speakers: Rob Allen, Ph.D. Managing Partner and General Manager Europe, Dark Horse Consulting Group Inc. Sarah Creviston Global Vice President, Patient Advocacy and Public Affairs, Novartis Gene Therapies
-
-
It's almost time! If you're not yet signed up for this Thursday's Unbridled Excellence webinar on Unique Considerations for Development of IND Strategy for Viral and Non-Viral Gene Editing with Elizabeth Figueroa and Christina Fuentes, Ph.D., do so now! https://lnkd.in/g56N6Kzb This webinar will address development considerations for the evolving gene editing and delivery landscape, including viral and non-viral delivery vectors such as lipid nanoparticles (LNPs) and Adeno-Associated virus (AAV). Topics covered will include: * Clinical progress of gene editing tools and delivery vectors * Creation of a modular, prospectively designed IND roadmap that can be applied towards different gene editing products * Discussion around product development challenges particular to gene editing products
-
-
Going to Terrapinn's Advanced Therapies USA 2024 next week (Nov 12-13) in Philadelphia, PA? Be sure to watch for us on the exhibit floor. Sanjin Zvoni?, Liz Cauldwell, Anne Lamontagne, and Oliver Ball will be in attendance; reach out through the partnering system (or write to [email protected]) if you'd like to set up a meeting time.
-
-
We've got a lovely double-feature for you in the middle of November: two excellent webinars featuring DHC experts for you to attend! Sign up here (https://lnkd.in/g56N6Kzb) for Unbridled Excellence no. 10, in which Elizabeth Figueroa and Christina Fuentes, Ph.D. will present on the topic of "Unique Considerations for Development of IND Strategy for Viral and Non-Viral Gene Editing" on Nov 14th at 9 am Pacific. ....and here (https://lnkd.in/gEG8xKXe) to hear from Rob Allen, MP and GM of DHC Europe, in Alliance for Regenerative Medicine's "Commercialization Strategies for Cell and Gene Therapies" webinar at 8 am Pacific on November 20th as part of the Building the Future of Regenerative Medicine webinar series. This webinar will explore the critical steps required to successfully bring cell and gene therapies to market. Experts will discuss strategies for navigating regulatory landscapes, securing funding, scaling manufacturing processes, and achieving market access. Attendees will gain insights into overcoming challenges and leveraging opportunities to ensure the commercial success of these groundbreaking therapies. Plan ahead, and enjoy!
-
-
If you aren't on our Quarter Horse newsletter list (you can do so here: https://lnkd.in/gKybnQba) then you will have missed reading the story of how DHC and BTL joined forces. Read the discussion with DHC's Executive Leadership Team and BTL's Founders here: https://lnkd.in/g2b2JUtq
-